Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila
Top Cited Papers
Open Access
- 22 September 2017
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 8, 1765
- https://doi.org/10.3389/fmicb.2017.01765
Abstract
Metabolic disorders associated with obesity and cardiometabolic disorders are worldwide epidemic. Among the different environmental factors, the gut microbiota is now considered as a key player interfering with energy metabolism and host susceptibility to several non-communicable diseases. Among the next- generation beneficial microbes that have been identified, Akkermansia muciniphila is a promising candidate. Indeed, A. muciniphila is inversely associated with obesity, diabetes, cardiometabolic diseases and low-grade inflammation. Besides the numerous correlations observed, a large body of evidence has demonstrated the causal beneficial impact of this bacterium in a variety of preclinical models. Translating these exciting observations to human would be the next logic step and it now appears that several obstacles that would prevent the use of A.muciniphila administration in humans have been overcome. Moreover, several lines of evidence indicate that pasteurization of A. muciniphila not only increases its stability but more importantly increases its efficacy. This strongly positions A. muciniphila in the forefront of next- generation candidates for developing novel food or pharma supplements with beneficial effects. Finally, a specific protein present on the outer membrane of A. muciniphila, termed Amuc_1100, could be strong candidate for future drug development. In conclusion, as plants and its related knowledge, known as pharmacognosy, have been the source for designing drugs over the last century, we propose that microbes and microbiomegnosy, or knowledge of our gut microbiome, can become a novel source of future therapies.Keywords
Funding Information
- European Research Council (336452-ENIGMO, Microbes4U_713547, 250172)
- Fonds De La Recherche Scientifique - FNRS (T.0138.14)
This publication has 73 references indexed in Scilit:
- Human Gut Microbiota Changes Reveal the Progression of Glucose IntolerancePLOS ONE, 2013
- Human milk metagenome: a functional capacity analysisBMC Microbiology, 2013
- Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesityProceedings of the National Academy of Sciences of the United States of America, 2013
- Gut Microbiota Is a Key Modulator of Insulin Resistance in TLR 2 Knockout MicePLoS Biology, 2011
- Responses of Gut Microbiota and Glucose and Lipid Metabolism to Prebiotics in Genetic Obese and Diet-Induced Leptin-Resistant MiceDiabetes, 2011
- Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatmentEMBO Molecular Medicine, 2011
- Consumption of diets high in prebiotic fiber or protein during growth influences the response to a high fat and sucrose diet in adulthood in ratsNutrition & Metabolism, 2010
- Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityGut, 2009
- The Mucin Degrader Akkermansia muciniphila Is an Abundant Resident of the Human Intestinal TractApplied and Environmental Microbiology, 2008
- Intestinal Integrity and Akkermansia muciniphila , a Mucin-Degrading Member of the Intestinal Microbiota Present in Infants, Adults, and the ElderlyApplied and Environmental Microbiology, 2007